Explore › Condition › non-valvular atrial fibrillation
Condition

non-valvular atrial fibrillation

Also known as: non-valvular atrial fibrillation
3 findings 1 paper 3 related entities View in graph →

Related entities

interventions
Oral anticoagulation1
outcomes
Rate of speech1
studys
PMC55643941

Findings (27)

None
adverse

Among atrial fibrillation patients under 60 with no structural heart disease and stroke risk scores of zero, approximately one in four (23.3-26.6%) were prescribed oral anticoagulants despite guidelin

Effect: adverse; 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescribed oral anticoagulants

Size: 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescr
PMC5564394
Finding details → · Paper → · Graph →
None
adverse

Among atrial fibrillation patients under 60 with no structural heart disease and stroke risk scores of zero, approximately one in four (23.3-26.6%) were prescribed oral anticoagulants despite guidelin

Effect: adverse; 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescribed oral anticoagulants

Size: 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescr
PMC5564394
Finding details → · Paper → · Graph →
None
adverse

Among atrial fibrillation patients under 60 with no structural heart disease and stroke risk scores of zero, approximately one in four (23.3-26.6%) were prescribed oral anticoagulants despite guidelin

Effect: adverse; 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescribed oral anticoagulants

Size: 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescr
PMC5564394
Finding details → · Paper → · Graph →
None
adverse

Among atrial fibrillation patients under 60 with no structural heart disease and stroke risk scores of zero, approximately one in four (23.3-26.6%) were prescribed oral anticoagulants despite guidelin

Effect: adverse; 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescribed oral anticoagulants

Size: 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescr
PMC5564394
Finding details → · Paper → · Graph →
None
adverse

Among atrial fibrillation patients under 60 with no structural heart disease and stroke risk scores of zero, approximately one in four (23.3-26.6%) were prescribed oral anticoagulants despite guidelin

Effect: adverse; 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescribed oral anticoagulants

Size: 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescr
PMC5564394
Finding details → · Paper → · Graph →
None
adverse

Among atrial fibrillation patients under 60 with no structural heart disease and stroke risk scores of zero, approximately one in four (23.3-26.6%) were prescribed oral anticoagulants despite guidelin

Effect: adverse; 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescribed oral anticoagulants

Size: 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescr
PMC5564394
Finding details → · Paper → · Graph →
None
adverse

Among atrial fibrillation patients under 60 with no structural heart disease and stroke risk scores of zero, approximately one in four (23.3-26.6%) were prescribed oral anticoagulants despite guidelin

Effect: adverse; 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescribed oral anticoagulants

Size: 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescr
PMC5564394
Finding details → · Paper → · Graph →
None
adverse

Among atrial fibrillation patients under 60 with no structural heart disease and stroke risk scores of zero, approximately one in four (23.3-26.6%) were prescribed oral anticoagulants despite guidelin

Effect: adverse; 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescribed oral anticoagulants

Size: 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescr
PMC5564394
Finding details → · Paper → · Graph →
None
adverse

Among atrial fibrillation patients under 60 with no structural heart disease and stroke risk scores of zero, approximately one in four (23.3-26.6%) were prescribed oral anticoagulants despite guidelin

Effect: adverse; 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescribed oral anticoagulants

Size: 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescr
PMC5564394
Finding details → · Paper → · Graph →
None
adverse

Among atrial fibrillation patients under 60 with no structural heart disease and stroke risk scores of zero, approximately one in four (23.3-26.6%) were prescribed oral anticoagulants despite guidelin

Effect: adverse; 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescribed oral anticoagulants

Size: 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescr
PMC5564394
Finding details → · Paper → · Graph →
None
adverse

Among atrial fibrillation patients under 60 with no structural heart disease and stroke risk scores of zero, approximately one in four (23.3-26.6%) were prescribed oral anticoagulants despite guidelin

Effect: adverse; 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescribed oral anticoagulants

Size: 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescr
PMC5564394
Finding details → · Paper → · Graph →
None
adverse

Among atrial fibrillation patients under 60 with no structural heart disease and stroke risk scores of zero, approximately one in four (23.3-26.6%) were prescribed oral anticoagulants despite guidelin

Effect: adverse; 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescribed oral anticoagulants

Size: 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescr
PMC5564394
Finding details → · Paper → · Graph →
None
adverse

Among atrial fibrillation patients under 60 with no structural heart disease and stroke risk scores of zero, approximately one in four (23.3-26.6%) were prescribed oral anticoagulants despite guidelin

Effect: adverse; 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescribed oral anticoagulants

Size: 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescr
PMC5564394
Finding details → · Paper → · Graph →
None
adverse

Among atrial fibrillation patients under 60 with no structural heart disease and stroke risk scores of zero, approximately one in four (23.3-26.6%) were prescribed oral anticoagulants despite guidelin

Effect: adverse; 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescribed oral anticoagulants

Size: 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescr
PMC5564394
Finding details → · Paper → · Graph →
None
adverse

Among atrial fibrillation patients under 60 with no structural heart disease and stroke risk scores of zero, approximately one in four (23.3-26.6%) were prescribed oral anticoagulants despite guidelin

Effect: adverse; 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescribed oral anticoagulants

Size: 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescr
PMC5564394
Finding details → · Paper → · Graph →
None
adverse

Among atrial fibrillation patients under 60 with no structural heart disease and stroke risk scores of zero, approximately one in four (23.3-26.6%) were prescribed oral anticoagulants despite guidelin

Effect: adverse; 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescribed oral anticoagulants

Size: 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescr
PMC5564394
Finding details → · Paper → · Graph →
None
adverse

Among atrial fibrillation patients under 60 with no structural heart disease and stroke risk scores of zero, approximately one in four (23.3-26.6%) were prescribed oral anticoagulants despite guidelin

Effect: adverse; 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescribed oral anticoagulants

Size: 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescr
PMC5564394
Finding details → · Paper → · Graph →
None
adverse

Among atrial fibrillation patients under 60 with no structural heart disease and stroke risk scores of zero, approximately one in four (23.3-26.6%) were prescribed oral anticoagulants despite guidelin

Effect: adverse; 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescribed oral anticoagulants

Size: 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescr
PMC5564394
Finding details → · Paper → · Graph →
None
adverse

Among atrial fibrillation patients under 60 with no structural heart disease and stroke risk scores of zero, approximately one in four (23.3-26.6%) were prescribed oral anticoagulants despite guidelin

Effect: adverse; 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescribed oral anticoagulants

Size: 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescr
PMC5564394
Finding details → · Paper → · Graph →
None
adverse

Among atrial fibrillation patients under 60 with no structural heart disease and stroke risk scores of zero, approximately one in four (23.3-26.6%) were prescribed oral anticoagulants despite guidelin

Effect: adverse; 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescribed oral anticoagulants

Size: 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescr
PMC5564394
Finding details → · Paper → · Graph →
None
adverse

Among atrial fibrillation patients under 60 with no structural heart disease and stroke risk scores of zero, approximately one in four (23.3-26.6%) were prescribed oral anticoagulants despite guidelin

Effect: adverse; 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescribed oral anticoagulants

Size: 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescr
PMC5564394
Finding details → · Paper → · Graph →
None
adverse

Among atrial fibrillation patients under 60 with no structural heart disease and stroke risk scores of zero, approximately one in four (23.3-26.6%) were prescribed oral anticoagulants despite guidelin

Effect: adverse; 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescribed oral anticoagulants

Size: 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescr
PMC5564394
Finding details → · Paper → · Graph →
None
adverse

Among atrial fibrillation patients under 60 with no structural heart disease and stroke risk scores of zero, approximately one in four (23.3-26.6%) were prescribed oral anticoagulants despite guidelin

Effect: adverse; 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescribed oral anticoagulants

Size: 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescr
PMC5564394
Finding details → · Paper → · Graph →
None
adverse

Among atrial fibrillation patients under 60 with no structural heart disease and stroke risk scores of zero, approximately one in four (23.3-26.6%) were prescribed oral anticoagulants despite guidelin

Effect: adverse; 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescribed oral anticoagulants

Size: 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescr
PMC5564394
Finding details → · Paper → · Graph →
None
adverse

Among atrial fibrillation patients under 60 with no structural heart disease and stroke risk scores of zero, approximately one in four (23.3-26.6%) were prescribed oral anticoagulants despite guidelin

Effect: adverse; 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescribed oral anticoagulants

Size: 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescr
PMC5564394
Finding details → · Paper → · Graph →
None
adverse

Among atrial fibrillation patients under 60 with no structural heart disease and stroke risk scores of zero, approximately one in four (23.3-26.6%) were prescribed oral anticoagulants despite guidelin

Effect: adverse; 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescribed oral anticoagulants

Size: 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescr
PMC5564394
Finding details → · Paper → · Graph →
None
adverse

Among atrial fibrillation patients under 60 with no structural heart disease and stroke risk scores of zero, approximately one in four (23.3-26.6%) were prescribed oral anticoagulants despite guidelin

Effect: adverse; 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescribed oral anticoagulants

Size: 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescr
PMC5564394
Finding details → · Paper → · Graph →

Papers (1)